Relationship between serum cystatin C and serum adiponectin level in type 2 diabetic patients

Clinical and Experimental Nephrology

Volumn 16, Issue 3, 2012, Pages 399-405

  Hosokawa, Yoshiya ^a   Yamada, Yuya ^a   Obata, Yoshinari ^a   Baden, Megu Yamaguchi ^a   Saisho, Kenji ^a   Ihara, Arisa ^a   Yamamoto, Koji ^a   Katsuragi, Kiyonori ^b   Matsuzawa, Yuji ^a  

^a SUMITOMO HOSPITAL   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Adipocytokine; Cystatin C; Diabetic nephropathy; Metabolic syndrome

Indexed keywords

ADIPONECTIN; ALBUMIN; CREATININE; CYSTATIN C; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADIPONECTIN BLOOD LEVEL; ADULT; AGE; AGED; ALBUMINURIA; ARTERIOSCLEROSIS; ARTICLE; BLOOD ANALYSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CYSTATIN C BLOOD LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE DURATION; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

ADIPONECTIN; ADULT; AGED; BLOOD PRESSURE; CHOLESTEROL, HDL; CREATININE; CYSTATIN C; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; SEX FACTORS; URIC ACID;

EID: 84863718414     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0571-5     Document Type: Article

References (29)

1. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 2009; 257:79-83.
2. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes. 2002;51:1884-8.
3. Matsuzawa Y. Adiponectin: A key player in obesity related disorders. Curr Pharm Des. 2010;16:1896-901.
4. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002;360:57-8.
5. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85-9.
6. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730-7.
7. Fujita H, Morii T, Koshimura J, Ishikawa M, Kato M, Miura T, et al. Possible relationship between adiponectin and renal tubular injury in diabetic nephropathy. Endocr J. 2006;53:745-52.
8. George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart. 2006;92:1420-4.
9. Imagawa A, Funahashi T, Nakamura T, Moriwaki M, Tanaka S, Nishizawa H, et al. Elevated serum concentration of adiposederived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care. 2002;25:1665.
10. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-266.
11. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-69.
12. Krolewski AS, Warram JH, Rand LI, Kahn CR. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med. 1987;317:1390-8.
13. Masaie H, Oritani K, Yokota T, Takahashi I, Shirogane T, Ujiie H, et al. Adiponectin binds to chemokines via the globular head and modulates interactions between chemokines and heparan sulfates. Exp Hematol. 2007;35:947-56.
14. Komura N, Kihara S, Sonoda M, Maeda N, Tochino Y, Funahashi T, et al. Increment and impairment of adiponectin in renal failure. Cardiovasc Res. 2010;86:471-7.
15. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-Analysis. Am J Kidney Dis. 2002;40:221-6.
16. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049-60.
17. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: Data from the Heart and Soul Study. Circulation. 2007;115:173-9.
18. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc. 2010;53:450-67 (article in Japanese).
19. Japanese Society of Nephrology. Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol. 2009;13:537-66.
20. Tanaka M, Matsuo K, Enomoto M, Mizuno K. A sol particle homogeneous immunoassay for measuring serum cystatin C. Clin Biochem. 2004;37:27-35.
21. Nishimura A, Sawai T. Determination of adiponectin in serum using a latex particle-enhanced turbidimetric immunoassay with an automated analyzer. Clin Chim Acta. 2006;371:163-8.
22. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002;106:2767-70.
23. Baden MY, Obata Y, Hosakawa Y, Saisho K, Tamba S, Yamamoto K, et al. Effects of alcohol drinking and smoking habit on serum adiponectin level in both diabetic and non-diabetic subjects. J Metab Syndr (in press) (article in Japanese).
24. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118:1645-56.
25. Tsioufis C, Dimitriadis K, Chatzis D, Vasiliadou C, Tousoulis D, Papademetriou V, et al. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol. 2005;96:946-51.
26. von Eynatten M, Liu D, Hock C, Oikonomou D, Baumann M, Allolio B, et al. Urinary adiponectin excretion: A novel marker for vascular damage in type 2 diabetes. Diabetes. 2009;58:2093-9.
27. Tsuda S, Nakano S, Konishi K, Koya D. A lack of increase in high molecular weight-Adiponectin in macroalbuminuric subjects with metabolic syndrome may exert renal and atherosclerotic risks. Diabetes Res Clin Pract. 2008;79:503-9.
28. Kato K, Osawa H, Ochi M, Kusunoki Y, Ebisui O, Ohno K, et al. Serum total and high molecular weight adiponectin levels are correlated with the severity of diabetic retinopathy and nephropathy. Clin Endocrinol (Oxf). 2008;68:442-9.
29. Krizer JR, Barzilay JI, Kuller LH, Gottdiener JS. Adiponectin and risk of coronary heart disease in older men and women. J Clin Endocrinol Metab. 2008;93:3357-64.